Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Research agenda and related workforce requirements inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research Collaborative.
Journal: Expert review of hematology
Published: August 07, 2026
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: March 29, 2022
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Journal: Research and practice in thrombosis and haemostasis
Published: November 16, 2021
A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A.
Journal: Journal of clinical pharmacology
Published: June 02, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: December 22, 2020
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Journal: Thrombosis and haemostasis
Published: October 21, 2020
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
Journal: Pediatric blood & cancer
Published: December 23, 2019
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
Journal: Journal of thrombosis and haemostasis : JTH
Published: March 19, 2019
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Journal: The Lancet. Haematology
Published: December 20, 2018
Last Updated: 09/26/2026